PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

PURPOSE OF REVIEW: The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS: Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atheroscler...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, M. John, Stock, Jane K., Ginsberg, Henry N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927326/
https://www.ncbi.nlm.nih.gov/pubmed/26780005
http://dx.doi.org/10.1097/MOL.0000000000000239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927326/
https://www.ncbi.nlm.nih.gov/pubmed/26780005
http://dx.doi.org/10.1097/MOL.0000000000000239

Ejemplares similares